These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 36204107)
21. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Purohit A; Fusi L; Brosens J; Woo LW; Potter BV; Reed MJ Hum Reprod; 2008 Feb; 23(2):290-7. PubMed ID: 18056119 [TBL] [Abstract][Full Text] [Related]
22. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Zeitoun KM; Bulun SE Fertil Steril; 1999 Dec; 72(6):961-9. PubMed ID: 10593363 [TBL] [Abstract][Full Text] [Related]
23. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319 [TBL] [Abstract][Full Text] [Related]
24. Site-Specific Regulation of Sulfatase and Aromatase Pathways for Estrogen Production in Endometriosis. Da Costa KA; Malvezzi H; Dobo C; Neme RM; Filippi RZ; Aloia TPA; Prado ER; Meola J; Piccinato CA Front Mol Biosci; 2022; 9():854991. PubMed ID: 35591944 [TBL] [Abstract][Full Text] [Related]
25. Endometriosis: the pathophysiology as an estrogen-dependent disease. Kitawaki J; Kado N; Ishihara H; Koshiba H; Kitaoka Y; Honjo H J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):149-55. PubMed ID: 12650711 [TBL] [Abstract][Full Text] [Related]
26. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. Delvoux B; Groothuis P; D'Hooghe T; Kyama C; Dunselman G; Romano A J Clin Endocrinol Metab; 2009 Mar; 94(3):876-83. PubMed ID: 19088158 [TBL] [Abstract][Full Text] [Related]
27. Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for Salah M; Tahoun M; Rudzitis-Auth J; Stotz L; van Koppen CJ; Laschke MW; Abdelsamie AS; Frotscher M J Med Chem; 2023 Jul; 66(13):8975-8992. PubMed ID: 37369108 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of excessive estrogen formation in endometriosis. Bulun SE; Gurates B; Fang Z; Tamura M; Sebastian S; Zhou J; Amin S; Yang S J Reprod Immunol; 2002; 55(1-2):21-33. PubMed ID: 12062819 [TBL] [Abstract][Full Text] [Related]
29. Aromatase and intracrinology of estrogen in hormone-dependent tumors. Harada N Oncology; 1999 Oct; 57 Suppl 2():7-16. PubMed ID: 10545798 [TBL] [Abstract][Full Text] [Related]
30. High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Cornel KM; Krakstad C; Delvoux B; Xanthoulea S; Jori B; Bongers MY; Konings GF; Kooreman LF; Kruitwagen RF; Salvesen HB; ; Romano A Mol Cell Endocrinol; 2017 Feb; 442():51-57. PubMed ID: 27923582 [TBL] [Abstract][Full Text] [Related]
31. Role of aromatase in endometrial disease. Bulun SE; Yang S; Fang Z; Gurates B; Tamura M; Zhou J; Sebastian S J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):19-25. PubMed ID: 11850203 [TBL] [Abstract][Full Text] [Related]
33. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544 [TBL] [Abstract][Full Text] [Related]
34. A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date. Peitsidis P; Tsikouras P; Laganà AS; Laios A; Gkegkes ID; Iavazzo C Drug Des Devel Ther; 2023; 17():1329-1346. PubMed ID: 37168488 [TBL] [Abstract][Full Text] [Related]
36. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869 [TBL] [Abstract][Full Text] [Related]
37. Anti-tumor effect of Shu-Gan-Liang-Xue decoction in breast cancer is related to the inhibition of aromatase and steroid sulfatase expression. Zhou N; Han SY; Zhou F; Li PP J Ethnopharmacol; 2014 Jul; 154(3):687-95. PubMed ID: 24809288 [TBL] [Abstract][Full Text] [Related]
38. Advances in targeting estrogen synthesis and receptors in patients with endometriosis. Clemenza S; Vannuccini S; Ruotolo A; Capezzuoli T; Petraglia F Expert Opin Investig Drugs; 2022 Nov; 31(11):1227-1238. PubMed ID: 36529967 [TBL] [Abstract][Full Text] [Related]
39. The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. Secky L; Svoboda M; Klameth L; Bajna E; Hamilton G; Zeillinger R; Jäger W; Thalhammer T J Drug Deliv; 2013; 2013():957605. PubMed ID: 23476785 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions. Delvoux B; D'Hooghe T; Kyama C; Koskimies P; Hermans RJ; Dunselman GA; Romano A J Clin Endocrinol Metab; 2014 Jan; 99(1):276-84. PubMed ID: 24187399 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]